摘要
本文中,我们队免疫乳腺癌的预后和预测标记物中有关癌症微环境的基质组分和免疫参数 的数据进行了总结。由于近期免疫治疗的突破,癌症的宿主免疫应答突显其重要性。目前,在不考虑基质成分重要性的情况下,乳腺癌的分子和临床分型仅仅是依据癌细胞的分子特征。有明显的证据表明浸润免疫和炎症细胞会影响胸腺癌的生物学和临床疗程。然而,免疫细胞的预后和预测功能不同于乳腺癌亚型。三阴性和HER2阳性乳腺癌中预后和预测标志物可以建立和确定免疫参数。 免疫参数也许可以作为临床试验的 多层参数临床决策中的辅助变量。另一方面,最低级、管腔A型乳腺癌中的预后和预测影响是最低的。三阴性乳腺癌和HER2阳性乳腺癌中较高的淋巴细胞浸润和更好的结果(包括更高的化疗敏感度)之间较强联系,也会提高以免疫细胞为靶点增强活性新的治疗方式的选择。免疫标志物具有作为预测性指标的潜力,为病人选择免疫治疗方案(如调定点阻滞剂)。
关键词: 乳腺癌,宿主因素,免疫细胞,免疫调节点,免疫治疗,预后,肿瘤浸润淋巴细胞
图形摘要
Current Cancer Drug Targets
Title:The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers
Volume: 15 Issue: 8
Author(s): Thomas Karn, Lajos Pusztai, Achim Rody, Uwe Holtrich and Sven Becker
Affiliation:
关键词: 乳腺癌,宿主因素,免疫细胞,免疫调节点,免疫治疗,预后,肿瘤浸润淋巴细胞
摘要: In this paper, we will review the data on stromal components and immunological parameters in the cancer microenvironment as prognostic and predictive markers in breast cancer. Host immunological response to cancer has gained importance because of recent breakthroughs in immunotherapy. Currently, molecular and clinical subtyping of breast cancer is solely based on the molecular features of the cancer cells without considering the importance of stromal components. There is now clear evidence that infiltrating immune and inflammatory cells influence the biology and clinical course of breast cancer. However, the prognostic and predictive function of immune cells differs between breast cancer subtypes. Immune parameters are established and validated prognostic and predictive markers in triple negative and for HER2 positive breast cancers and may be ready to be used as stratification parameters in clinical trials and as adjunct variables when making clinical decisions. On the other hand, the prognostic and predictive impact is minimal in low grade, luminal A type breast cancers. The strong association between higher lymphocytic infiltration and better outcome (including greater chemotherapy sensitivity) in TNBC and HER2 positive cancers also raises novel therapeutic options that target immune cells to increase their activity. Immune markers also carry the potential to serve as predictive markers to select patients for immunotherapeutic regimens (e.g. checkpoint inhibitors).
Export Options
About this article
Cite this article as:
Thomas Karn, Lajos Pusztai, Achim Rody, Uwe Holtrich and Sven Becker , The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers, Current Cancer Drug Targets 2015; 15 (8) . https://dx.doi.org/10.2174/156800961508151001101209
DOI https://dx.doi.org/10.2174/156800961508151001101209 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Healthy Diet and Reduction of Chronic Disease Risks of Night Shift Workers
Current Medicinal Chemistry CXCR4-CXCL12-Dependent Inflammatory Network and Endothelial Progenitors
Current Medicinal Chemistry Modulation of Angiogenesis by Inflammatory Markers and the Role of Matrix Metalloproteinases in an Endothelial Cell/Fibroblast Co-culture System
Current Angiogenesis (Discontinued) Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Survivin for Radiation Oncology: Moving Beyond Apoptosis Inhibition
Current Medicinal Chemistry Immunotherapy for Prostate Cancer
Current Pharmaceutical Design Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?
Current Drug Metabolism Editorial [Hot topic: Membrane Estrogen Receptors (Guest Editor: Paul J. Davis)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Emerging Concepts on Inhibitors of Indoleamine 2,3-Dioxygenase in Rheumatic Diseases
Current Medicinal Chemistry Listeria monocytogenes as a Vector for Anti-Cancer Therapies
Current Gene Therapy Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'
Current Medicinal Chemistry Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry Preface
Current Pharmaceutical Design Eco-Friendly and Highly Efficient Multigram Synthesis of N-(2- Hydroxyethyl)-2-Oxo-2H-Chromene-3-Carboxamide as a Useful Intermediate Using Sonochemistry
Current Green Chemistry The Role of Bone Density Measurements in the Evaluation of New Treatments for Osteoporosis
Current Pharmaceutical Design Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Therapeutical Relevance of MAP-Kinase Inhibitors in Renal Diseases: Current Knowledge and Future Clinical Perspectives
Current Medicinal Chemistry Current Advances in the Synthesis and Biological Evaluation of Pharmacologically Relevant 1,2,4,5-Tetrasubstituted-1H-Imidazole Derivatives
Current Organic Chemistry